AFTER: Altering Fat Through Estrogen and Raloxifene
Completed · Phase 2
Conditions studied: Postmenopause
In brief
The purpose of this study is to determine whether estrogens specifically promote a reduction in fat from abdominal regions during weight loss and/or prevent the accumulation of abdominal fat during weight gain.
Key facts
- Study ID
- NCT00149604
- Run by
- National Institute on Aging (NIA)
- People needed
- 108
- Starts
- 2000-03-01
- Expected to finish
- 2006-02-01
- Last updated by the study team
- 2009-12-02
Who can join
Age: 50 and older, up to 70. Sex: female. Healthy volunteers: accepted.
You may qualify if…
- postmenopausal women
- aged 50-70 yr
- healthy, as determined by medical history, physical examination, blood chemistries, and a graded exercise stress test with monitoring of blood pressure and ECG
- good cognitive function.
You may not qualify if…
- contraindications to estrogen or raloxifene treatment, including history of or active breast cancer or other estrogen-dependent neoplasms, acute liver disease, undiagnosed vaginal bleeding, and active or history of blood clotting disorders
- mild or more severe cognitive impairment, indicated by a MMSE score <26
- clinically significant abnormal resting electrocardiogram (ECG), angina and/or ECG evidence of acute myocardial ischemia during a maximal exercise stress test
- resting blood pressure above 150 mmHg systolic or 90 mmHg diastolic
- left bundle branch blocks, A-V block greater than first degree, clinically significant arrhythmias
- congestive heart failure
- pulmonary emboli in the previous 6 months
- aortic stenosis
- chronic infections
- orthopedic or other problems that would interfere with participation in the exercise program
Where it is running
- University of Colorado at Denver and Health Sciences Center — Denver, Colorado, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.